tetano
Editor, Senior Moderator
Vaccines (Basel). 2018 Jun 26;6(3). pii: E35. doi: 10.3390/vaccines6030035.
[h=1]Neutralizing Anti-Hemagglutinin Monoclonal Antibodies Induced by Gene-Based Transfer Have Prophylactic and Therapeutic Effects on Influenza Virus Infection.[/h] Yamazaki T[SUP]1[/SUP], Chiba J[SUP]2[/SUP], Akashi-Takamura S[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Hemagglutinin (HA) of influenza virus is a major target for vaccines. HA initiates the internalization of the virus into the host cell by binding to host sialic acid receptors; therefore, inhibition of HA can significantly prevent influenza virus infection. However, the high diversity of HA permits the influenza virus to escape from host immunity. Moreover, the vaccine efficacy is poor in some high-risk populations (e.g., elderly or immunocompromised patients). Passive immunization with anti-HA monoclonal antibodies (mAbs) is an attractive therapy; however, this method has high production costs and requires repeated inoculations. To address these issues, several methods for long-term expression of mAb against influenza virus have been developed. Here, we provide an overview of methods using plasmid and viral adeno-associated virus (AAV) vectors that have been modified for higher expression of neutralizing antibodies in the host. We also examine two methods of injection, electro-transfer and hydrodynamic injection. Our results show that antibody gene transfer is effective against influenza virus infection even in immunocompromised mice, and antibody expression was detected in the serum and upper respiratory tract. We also demonstrate this method to be effective following influenza virus infection. Finally, we discuss the perspective of passive immunization with antibody gene transfer for future clinical trials.
[h=4]KEYWORDS:[/h] adeno-associated virus (AAV) vector; antibody drug; antibody-gene; electro-transfer; gene therapy; hemagglutinin; hydrodynamic injection; passive immune-prophylaxis; passive immune-therapy; plasmid vector
PMID: 29949942 DOI: 10.3390/vaccines6030035
[h=1]Neutralizing Anti-Hemagglutinin Monoclonal Antibodies Induced by Gene-Based Transfer Have Prophylactic and Therapeutic Effects on Influenza Virus Infection.[/h] Yamazaki T[SUP]1[/SUP], Chiba J[SUP]2[/SUP], Akashi-Takamura S[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Hemagglutinin (HA) of influenza virus is a major target for vaccines. HA initiates the internalization of the virus into the host cell by binding to host sialic acid receptors; therefore, inhibition of HA can significantly prevent influenza virus infection. However, the high diversity of HA permits the influenza virus to escape from host immunity. Moreover, the vaccine efficacy is poor in some high-risk populations (e.g., elderly or immunocompromised patients). Passive immunization with anti-HA monoclonal antibodies (mAbs) is an attractive therapy; however, this method has high production costs and requires repeated inoculations. To address these issues, several methods for long-term expression of mAb against influenza virus have been developed. Here, we provide an overview of methods using plasmid and viral adeno-associated virus (AAV) vectors that have been modified for higher expression of neutralizing antibodies in the host. We also examine two methods of injection, electro-transfer and hydrodynamic injection. Our results show that antibody gene transfer is effective against influenza virus infection even in immunocompromised mice, and antibody expression was detected in the serum and upper respiratory tract. We also demonstrate this method to be effective following influenza virus infection. Finally, we discuss the perspective of passive immunization with antibody gene transfer for future clinical trials.
[h=4]KEYWORDS:[/h] adeno-associated virus (AAV) vector; antibody drug; antibody-gene; electro-transfer; gene therapy; hemagglutinin; hydrodynamic injection; passive immune-prophylaxis; passive immune-therapy; plasmid vector
PMID: 29949942 DOI: 10.3390/vaccines6030035